Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter-Related Infections | 2 | 2024 | 139 | 0.860 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2022 | 14 | 0.780 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 71 | 0.740 |
Why?
|
| Histiocytosis, Langerhans-Cell | 4 | 2025 | 240 | 0.730 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.700 |
Why?
|
| Cross Infection | 1 | 2022 | 344 | 0.600 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 820 | 0.470 |
Why?
|
| Sepsis | 2 | 2025 | 519 | 0.310 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2025 | 222 | 0.250 |
Why?
|
| Histiocytes | 1 | 2025 | 25 | 0.240 |
Why?
|
| Neoplasms | 3 | 2025 | 3034 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 358 | 0.210 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2025 | 128 | 0.210 |
Why?
|
| Child | 11 | 2025 | 25911 | 0.200 |
Why?
|
| Thioguanine | 1 | 2022 | 22 | 0.200 |
Why?
|
| Mercaptopurine | 1 | 2022 | 72 | 0.190 |
Why?
|
| Anemia, Aplastic | 1 | 2022 | 62 | 0.190 |
Why?
|
| Chlorhexidine | 1 | 2022 | 49 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 285 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 106 | 0.180 |
Why?
|
| Dyspnea | 1 | 2022 | 160 | 0.180 |
Why?
|
| Quality Improvement | 2 | 2024 | 700 | 0.180 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 145 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 128 | 0.170 |
Why?
|
| Iron | 1 | 2022 | 305 | 0.160 |
Why?
|
| Sarcoma | 1 | 2022 | 209 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 620 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2022 | 211 | 0.150 |
Why?
|
| Mass Screening | 1 | 2025 | 843 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 490 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 772 | 0.150 |
Why?
|
| Fourth Ventricle | 1 | 2017 | 10 | 0.140 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2017 | 16 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1187 | 0.120 |
Why?
|
| Humans | 15 | 2025 | 134145 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1772 | 0.100 |
Why?
|
| Hypertension | 1 | 2022 | 1407 | 0.100 |
Why?
|
| Infant | 4 | 2025 | 13256 | 0.070 |
Why?
|
| Male | 6 | 2025 | 66171 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2025 | 14895 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1853 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1164 | 0.060 |
Why?
|
| Adolescent | 4 | 2025 | 20643 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 27 | 0.060 |
Why?
|
| Child, Hospitalized | 1 | 2025 | 76 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 42 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 33 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 365 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2025 | 320 | 0.050 |
Why?
|
| HLA-B Antigens | 1 | 2022 | 30 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 202 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 107 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 221 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 202 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2022 | 322 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 826 | 0.040 |
Why?
|
| Young Adult | 2 | 2025 | 9960 | 0.040 |
Why?
|
| Female | 5 | 2025 | 72003 | 0.040 |
Why?
|
| Recurrence | 1 | 2024 | 1470 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1097 | 0.040 |
Why?
|
| Adult | 3 | 2025 | 31943 | 0.040 |
Why?
|
| Rosette Formation | 1 | 2017 | 6 | 0.030 |
Why?
|
| Alleles | 1 | 2022 | 1724 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1344 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 795 | 0.030 |
Why?
|
| Hospitalization | 1 | 2025 | 1908 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 4006 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2203 | 0.030 |
Why?
|
| Middle Aged | 2 | 2025 | 29395 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6610 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2025 | 2588 | 0.020 |
Why?
|
| Mutation | 1 | 2025 | 6342 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4802 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 11184 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 13098 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21789 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 19043 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 36518 | 0.010 |
Why?
|